About 1 in 8 American adults now reports taking a GLP-1 drug, according to a recent KFF survey, and the effects are radiating far beyond doctor's offices. [1] What began as a diabetes treatment has become a social phenomenon reshaping how people date, what they eat, how they dress, and whether their insurance will pay for any of it.

The Business of Fashion reported in January that GLP-1 adoption is driving measurable shifts in beauty and fashion retail. Clothing brands are seeing demand shift toward smaller sizes. Luxury houses are adjusting fit models. The recently launched Wegovy pill -- an oral alternative to weekly injections -- is expected to accelerate uptake further among people who avoided needles.

CNBC documented in February how GLP-1 users describe unexpected changes: reduced alcohol cravings, altered food preferences, and shifts in dating confidence. Dating apps have seen users reference GLP-1 status in profiles. Some users report the drugs changed not just their weight but their relationship to food, socializing, and self-image.

The insurance landscape is in flux. Forbes reported that as of January, several major insurers dropped obesity drug coverage even as Medicare and Medicaid expanded access. The cost -- roughly $1,000 per month without coverage -- creates a two-tier system where access tracks income.

PwC identified GLP-1 drugs as the single largest disruptor to consumer-facing business models in 2026, with effects touching restaurants, grocery, fitness, and apparel. The food industry is already responding: portion sizes at major chains are shrinking, and "GLP-1 friendly" menu labels have appeared.

The medical revolution is now a cultural one.

-- NORA WHITFIELD, New York